Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 4.55
MYND's Cash-to-Debt is ranked higher than
53% of the 261 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.52 vs. MYND: 4.55 )
Ranked among companies with meaningful Cash-to-Debt only.
MYND' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 3.38 Max: No Debt
Current: 4.55
0
No Debt
Equity-to-Asset 0.66
MYND's Equity-to-Asset is ranked lower than
72% of the 239 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. MYND: 0.66 )
Ranked among companies with meaningful Equity-to-Asset only.
MYND' s Equity-to-Asset Range Over the Past 10 Years
Min: -105.6  Med: -4.28 Max: 0.91
Current: 0.66
-105.6
0.91
Debt-to-Equity 0.19
MYND's Debt-to-Equity is ranked higher than
59% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.36 vs. MYND: 0.19 )
Ranked among companies with meaningful Debt-to-Equity only.
MYND' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.6  Med: -0.31 Max: 0.75
Current: 0.19
-1.6
0.75
Debt-to-EBITDA -0.05
MYND's Debt-to-EBITDA is ranked lower than
99.99% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.77 vs. MYND: -0.05 )
Ranked among companies with meaningful Debt-to-EBITDA only.
MYND' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.05  Med: -0.02 Max: 0
Current: -0.05
-1.05
0
Piotroski F-Score: 3
Altman Z-Score: -4.56
Beneish M-Score: 5.76
WACC vs ROIC
6.44%
3730.79%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -1090.87
MYND's Operating Margin % is ranked lower than
97% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.59 vs. MYND: -1090.87 )
Ranked among companies with meaningful Operating Margin % only.
MYND' s Operating Margin % Range Over the Past 10 Years
Min: -5506.98  Med: -3017.14 Max: -707.24
Current: -1090.87
-5506.98
-707.24
Net Margin % -1059.72
MYND's Net Margin % is ranked lower than
97% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.48 vs. MYND: -1059.72 )
Ranked among companies with meaningful Net Margin % only.
MYND' s Net Margin % Range Over the Past 10 Years
Min: -8325.95  Med: -3170.81 Max: -694.06
Current: -1059.72
-8325.95
-694.06
ROE % -500.28
MYND's ROE % is ranked lower than
98% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.75 vs. MYND: -500.28 )
Ranked among companies with meaningful ROE % only.
MYND' s ROE % Range Over the Past 10 Years
Min: -500.28  Med: -288.14 Max: -167.72
Current: -500.28
-500.28
-167.72
ROA % -252.70
MYND's ROA % is ranked lower than
98% of the 262 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.54 vs. MYND: -252.70 )
Ranked among companies with meaningful ROA % only.
MYND' s ROA % Range Over the Past 10 Years
Min: -2916.78  Med: -775.16 Max: -124.27
Current: -252.7
-2916.78
-124.27
ROC (Joel Greenblatt) % -8983.66
MYND's ROC (Joel Greenblatt) % is ranked lower than
98% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -9.57 vs. MYND: -8983.66 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MYND' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -70800  Med: -29361.54 Max: -2714.29
Current: -8983.66
-70800
-2714.29
3-Year Revenue Growth Rate -44.70
MYND's 3-Year Revenue Growth Rate is ranked lower than
94% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. MYND: -44.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MYND' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -75.2 Max: -3.6
Current: -44.7
3-Year EBITDA Growth Rate 31.10
MYND's 3-Year EBITDA Growth Rate is ranked higher than
81% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. MYND: 31.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MYND' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -1322.4  Med: 7.2 Max: 78.6
Current: 31.1
-1322.4
78.6
3-Year EPS without NRI Growth Rate 25.10
MYND's 3-Year EPS without NRI Growth Rate is ranked higher than
71% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. MYND: 25.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MYND' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 2 Max: 81.1
Current: 25.1
0
81.1
GuruFocus has detected 7 Warning Signs with MYnd Analytics Inc MYND.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MYND's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with MYND

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325412    SIC: 2834
Compare:NAS:ATOS, BOM:516110, XCNQ:BTH, XSAT:ISAB, XCNQ:RLSC, OSTO:KONT, XSAT:ACOU, NAS:NDRA, LSE:GDR, OTCPK:DIGP, NAS:OPGN, NAS:PRPO, XSAT:BIBB, ASX:BD1, TSX:GEN, TSXV:DXD, ASX:IBX, ASX:PAA, ASX:LSH, OTCPK:MHTX » details
Traded in other countries:BBOT.Germany,
Headquarter Location:USA
MYnd Analytics Inc is a cloud-based predictive analytics company. It provides clinical decision support to mental healthcare providers for the treatment of behavioral disorders, including depression, bipolar disorder and post-traumatic stress disorder.

MYnd Analytics Inc is a predictive analytics company. It mainly focuses on developing a decision support tool to help physicians reduce trial and error treatment in mental health and provide more personalized care to patients. The company provides objective clinical decision support to mental health care providers for the personalized treatment of behavioral disorders, including depression, anxiety, bipolar disorder, post-traumatic stress disorder (PTSD) and other non-psychotic disorders. In addition, the company also develops a proprietary neurometric platform, PEER Online to generate Psychiatric EEG Evaluation Registry (PEER) Reports predicting the likelihood of response by an individual to a range of medications prescribed for the treatment of behavioral disorders.

Top Ranked Articles about MYnd Analytics Inc

MYnd Analytics Partners with Inova Mount Vernon Hospital to Improve Mental Health Outcomes
MYnd Analytics Provides Business Update for the Third Quarter of 2018
MYnd Analytics Partners with VisionQuest to Provide Telepsychiatry Services for its Community-Based Outpatient Mental Health Clinic in Pennsylvania
MYnd Analytics and Arcadian Telepsychiatry Services Launch Comprehensive Behavioral Health Solution for Skilled Nursing and Assisted Living Facilities
MYnd Analytics Provides Business Update and Reports Significant Increase in Revenues for the Second Quarter of 2018
MYnd Analytics and Arcadian Telepsychiatry Services Announce Launch of School-Based Telepsychiatry Program Designed to Provide Youths with School-Based  Access to Mental Health Services
MYnd Completes $2.1 Million Dollar Private Placement by Company Insiders at Significant Premium to Market
Advanzeon Solutions, Inc. and MYnd Analytics, Inc. Announce Expanded Collaboration Between their Wholly Owned Subsidiaries, Pharmacy Value Management Solutions, Inc. and Arcadian Telepsychiatry Services
MYnd Analytics Awarded Canadian Patent on Neuromodulation Platform; Predicts Patients Likely to Respond to TMS for Treating Depression
MYnd Analytics’ Arcadian Telepsychiatry Services Featured on CBS New York

Ratios

vs
industry
vs
history
PB Ratio 2.48
MYND's PB Ratio is ranked lower than
53% of the 245 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.02 vs. MYND: 2.48 )
Ranked among companies with meaningful PB Ratio only.
MYND' s PB Ratio Range Over the Past 10 Years
Min: 2.34  Med: 7.37 Max: 525.55
Current: 2.48
2.34
525.55
PS Ratio 6.42
MYND's PS Ratio is ranked lower than
92% of the 230 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.81 vs. MYND: 6.42 )
Ranked among companies with meaningful PS Ratio only.
MYND' s PS Ratio Range Over the Past 10 Years
Min: 1.35  Med: 40.4 Max: 336.79
Current: 6.42
1.35
336.79
EV-to-EBIT -0.56
MYND's EV-to-EBIT is ranked lower than
99.99% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.06 vs. MYND: -0.56 )
Ranked among companies with meaningful EV-to-EBIT only.
MYND' s EV-to-EBIT Range Over the Past 10 Years
Min: -25.7  Med: -2.9 Max: -0.1
Current: -0.56
-25.7
-0.1
EV-to-EBITDA -0.56
MYND's EV-to-EBITDA is ranked lower than
99.99% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.75 vs. MYND: -0.56 )
Ranked among companies with meaningful EV-to-EBITDA only.
MYND' s EV-to-EBITDA Range Over the Past 10 Years
Min: -29.7  Med: -2.9 Max: -0.1
Current: -0.56
-29.7
-0.1
EV-to-Revenue 5.95
MYND's EV-to-Revenue is ranked lower than
88% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.24 vs. MYND: 5.95 )
Ranked among companies with meaningful EV-to-Revenue only.
MYND' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.5  Med: 62.1 Max: 685.7
Current: 5.95
0.5
685.7
Current Ratio 2.31
MYND's Current Ratio is ranked lower than
69% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.58 vs. MYND: 2.31 )
Ranked among companies with meaningful Current Ratio only.
MYND' s Current Ratio Range Over the Past 10 Years
Min: 0.01  Med: 0.28 Max: 11.26
Current: 2.31
0.01
11.26
Quick Ratio 2.31
MYND's Quick Ratio is ranked lower than
63% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. MYND: 2.31 )
Ranked among companies with meaningful Quick Ratio only.
MYND' s Quick Ratio Range Over the Past 10 Years
Min: 0.01  Med: 0.26 Max: 11.26
Current: 2.31
0.01
11.26
Days Sales Outstanding 49.61
MYND's Days Sales Outstanding is ranked lower than
82% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.51 vs. MYND: 49.61 )
Ranked among companies with meaningful Days Sales Outstanding only.
MYND' s Days Sales Outstanding Range Over the Past 10 Years
Min: 19.81  Med: 35.21 Max: 75.23
Current: 49.61
19.81
75.23
Days Payable 259.44
MYND's Days Payable is ranked lower than
97% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.34 vs. MYND: 259.44 )
Ranked among companies with meaningful Days Payable only.
MYND' s Days Payable Range Over the Past 10 Years
Min: 259.44  Med: 4541.62 Max: 61466
Current: 259.44
259.44
61466

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -103.50
MYND's 3-Year Average Share Buyback Ratio is ranked lower than
92% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.90 vs. MYND: -103.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MYND' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -270.8  Med: 0 Max: 63.4
Current: -103.5
-270.8
63.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 12.27
MYND's Price-to-Net-Cash is ranked lower than
74% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 14.60 vs. MYND: 12.27 )
Ranked among companies with meaningful Price-to-Net-Cash only.
MYND' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.59  Med: 7.55 Max: 56.67
Current: 12.27
2.59
56.67
Price-to-Net-Current-Asset-Value 7.50
MYND's Price-to-Net-Current-Asset-Value is ranked lower than
82% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.88 vs. MYND: 7.50 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
MYND' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.49  Med: 13.06 Max: 352.95
Current: 7.5
2.49
352.95
Price-to-Tangible-Book 4.82
MYND's Price-to-Tangible-Book is ranked lower than
84% of the 207 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.46 vs. MYND: 4.82 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
MYND' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.49  Med: 12.64 Max: 262.78
Current: 4.82
2.49
262.78
Price-to-Median-PS-Value 0.16
MYND's Price-to-Median-PS-Value is ranked higher than
72% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. MYND: 0.16 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MYND' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.09  Med: 1.6 Max: 4705.93
Current: 0.16
0.09
4705.93
Earnings Yield (Greenblatt) % -184.73
MYND's Earnings Yield (Greenblatt) % is ranked lower than
95% of the 265 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.98 vs. MYND: -184.73 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MYND' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1388.4  Med: -34.9 Max: -3.9
Current: -184.73
-1388.4
-3.9

More Statistics

Revenue (TTM) (Mil) $1.01
EPS (TTM) $ -2.32
Beta0.59
Volatility108.88%
52-Week Range $1.15 - 5.05
Shares Outstanding (Mil)6.28

Analyst Estimate

Sep18 Sep19 Sep20 Sep21
Revenue (Mil $) 8 31 65 133
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) -1.19 1.78 4.80 10.54
EPS without NRI ($) -1.19 1.78 4.80 10.54
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 33
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAY
Lower Leverage yoyN
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}